STOCKHOLM--(BUSINESS WIRE)--Regulatory News:
As of 30 June 2016, the total number of shares in Recipharm AB (publ) (“Recipharm”) amounts to 63,217,532 shares, divided into 15,222,858 shares of series A, 47,494,674 shares of series B and 500,000 shares of series D. The total number of votes in Recipharm as of 30 June 2016 amounts to 200,223,254.
As previously announced by Recipharm, the number of shares and votes in Recipharm has increased as a result of a cash issue of 2,537,142 shares of series A and 7,273,924 shares of series B with preferential rights for the shareholders of the Company in the amount of approximately SEK 805 million, and a cash issue of 631,914 shares of series B directed to the sellers of Kemwell AB in the amount of approximately SEK 52 million.
For further information please visit www.recipharm.com
This information is published in accordance with Chapter 4, Section 9 of the Swedish Financial Instruments Trading Act (SFS 1991:980).This information was submitted for publication on 30 June 2016, at 08:00 am CET.
Recipharm is a leading CDMO (Contract Development and Manufacturing Organisation) in the pharmaceutical industry employing some 3,500 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, and pharmaceutical product development. Recipharm manufactures several hundred different products to customers ranging from Big Pharma to smaller research- and development companies. Recipharm’s turnover is approximately SEK 5.0 billion and the Company operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US and is headquartered in Jordbro, Sweden. The Recipharm B-share (RECI B) is listed on Nasdaq Stockholm.
For more information on Recipharm and our services, please visit www.recipharm.com
Recipharm AB (publ)
Corporate identity number 556498-8425
Address Lagervägen 7, SE-136 50 Jordbro, Sweden, Telephone 46 8 602 52 00, Fax 46 8 81 87 03
This information was brought to you by Cision http://news.cision.com